**Trichodysplasia spinulosa in a renal transplant patient: A case report of successful treatment**

Camille Pennou¹, Eileen Javidi², Julie Lecours¹, Annie Bélisle³ and Sandra Davar¹

**Abstract**

Trichodysplasia spinulosa is a rare cutaneous disease caused by the trichodysplasia spinulosa–associated polyomavirus. It occurs more frequently in immunocompromised patients, particularly in solid organ transplants. A few successful treatments have been described in the literature. In our report, we present a biopsy-proven trichodysplasia spinulosa case in a kidney transplant recipient who rapidly responded to a reduction of his immunosuppressive therapy.

**Keywords**

Trichodysplasia spinulosa, immunosuppression, polyomavirus, renal transplant

**Introduction**

Trichodysplasia spinulosa (TS) is a rare cutaneous disease characterized by folliculocentric papules with keratin spicules primarily involving the central face. This condition is associated with the trichodysplasia spinulosa–associated polyomavirus (TSPyV), although precise mechanisms remain unknown. Here, we present a case of TS in a kidney transplant recipient who rapidly responded to a reduction of his immunosuppressive therapy.

**Case report**

A 61-year-old man with a past medical history of a kidney transplant in 2015 for polycystic kidneys presented to the dermatology clinic with complaints of multiple asymptomatic skin-colored papules on the face and ears, and some slightly pruritic pink papules on the trunk and extremities. These lesions appeared 1 year after transplant and were progressing for the past 2 years. In the last months, he also noticed hair loss on his eyebrows and limbs. His immunosuppressive regimen included tacrolimus, mycophenolate mofetil (MMF), and prednisone.

On clinical examination, there were multiple millimetric folliculocentric hyperkeratotic skin-colored to pink papules on the face (Figure 1), ears (Figure 2), trunk and extremities (Figure 3). Some of the papules also had a white central spicule. Furthermore, alopecia was noted on the eyebrows and extremities. Cutaneous biopsies of the thigh and back showed dilated follicles with eosinophilic trichohyalin granules and keratin debris that were replacing the hair shaft (Figures 4 and 5). Unfortunately, our center could not provide us with the real-time polymerase chain reaction (PCR) targeting the viral protein 1 ($VP1$) gene, so the diagnosis of TS associated with immunosuppression was made by clinical and histological findings.

After a discussion with the patient’s nephrologist, she preferred a reduction of the immunosuppressive medication instead of treating with a systemic retinoid. The MMF was reduced from 720 to 360 mg twice a day, and the tacrolimus from 4.5 to 4 mg once a day. A topical tretinoin gel 0.1% was also applied daily on facial lesions. At follow-up, 4 months later, a spectacular improvement of the facial lesions was noted. However, many papules persisted on the trunk and limbs. At the 6-month follow-up, there was a complete resolution of the facial, ears, and trunk lesions (Figures 6 and 7). Because some of the papules still persisted on the extremities, the tretinoin gel was pursued there.
Figure 1. Folliculocentric hyperkeratotic skin-colored to pink papules on the face.

Figure 2. Folliculocentric skin-colored papules with central spicules on the ears.

Figure 3. Folliculocentric hyperkeratotic pink papules on the extremities.

Figure 4. Cutaneous biopsy of the thigh showing dilated follicles with eosinophilic trichohyalin granules and keratin debris replacing the hair shaft (HPS: hematoxylin phloxine saffron staining, 20× magnification).

Discussion
TS is a rare entity first described in 1995 by Izakovic et al.¹ Seen in a renal transplant patient, it was regarded as a side effect of cyclosporine. In 1999, Haycox et al.² used electron
microscopy to identify small (38 nm), intracellular virus particles in the cutaneous biopsies belonging to the Papovaviridae family. Even though many immunohistochemical analyses were realized, distinction between papillomaviruses and polyomaviruses could not be made at that time. In 2010, Van der Meijden et al. used rolling-circle DNA amplification to isolate the virus from the spicules and named it TSPyV.

TS is almost exclusively observed in a context of immunosuppression, either in association with solid organ transplantations or hematologic malignancies. However, in 2014, one case of perioral TS was also described in a patient with the Gorlin syndrome undergoing treatment with vismodegib and another case in a patient with systemic lupus erythematosus under different immunosuppressants. This condition affects adults and children equally, and seems to appear between 6 months and 9 years post-transplant or after a diagnosis of hematologic malignancy.

The seroprevalence of TSPyV appears rather high in the general population, ranging from 70% to 90%, most frequently with exposure during childhood. However, instead of being caused by the reactivation of the virus, TS is thought to result from a primary infection in immunosuppressed patients.

Typically, TS diagnosis is made based on the combination of clinical and histopathologic evidence. However, other recent diagnosis methods—such as immunohistochemistry, scanning electron microscopy, and PCR—have been used to confirm the viral etiology. Clinically, TS is characterized by an eruption of follicular flesh-colored or pink papules frequently featuring central keratotic spicules. It mainly affects the central face, ears, and, in a lesser proportion, the trunk and the extremities. The lesions are most often asymptomatic although occasionally associated pruritus has been reported.
Typical complications include varying degrees of nonscarring alopecia, most frequently affecting the eyebrows, and skin thickening that can lead to a disfiguring leonine facies. Histopathology shows dilated hair follicles, with an expanded inner root sheath cells, keratotic debris, and enlarged eosinophilic trichohyalin granules. There are currently no established guidelines regarding TS treatment. Case reports have shown successful results with topical cidofovir 1%-3%, oral valganciclovir, and reduction in the immunosuppressive therapy. Other reported therapies included spicule extraction, oral and topical retinoids, biotics, imiquimod, and oral minocycline showed little or no improvement. In our case, a conservative treatment was privileged. After careful review of the patient’s renal condition and discussion with his nephrologist, we reduced immunosuppression, and added a tretinoin gel for facial lesions. The results were impressive since the patient was almost clear of lesions after 6 months. Our case report demonstrates that an extensive case of TS can resolve completely with a more conservative approach. So, instead of adding another medication, if the nephrologist or transplant physician is more inclined to securely reduce the immunosuppression and monitor it, this therapeutic strategy could be tried first before undergoing more aggressive treatments.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
A written informed consent for the patient informations and images was provided by the patient.

References
1. Izakovic J, Bächler SA, Düggelin M, et al. Hair-like hyperkeratoses in patients with kidney transplants. Hautarzt 1995; 46(12): 841–846.
2. Haycox CL, Kim S, Fleckman P, et al. Trichodysplasia spinulosa: a newly described folliculocentric viral infection in an immunocompromised host. J Invest Dermatol Symp Proc 1999; 4(3): 268–271.
3. Van der Meijden E, Janssens RW, Lauber C, et al. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog 2010; 6(7): 1–10.
4. Richey JD, Graham TA, Katona T, et al. Development of trichodysplasia spinulosa: case report of a patient with Gorlin syndrome treated with vismodegib. JAMA Dermatol 2014; 150(9): 1016–1018.
5. Moktefi A, Laude H and Brudy Gulphe L. Trichodysplasia spinulosa associated with lupus. Am J Dermatopathol 2014; 36(3): e70–e74.
6. Matthews MR, Wang RC, Reddick RL, et al. Viral-associated trichodysplasia spinulosa: a case with electron microscopic and molecular detection of the trichodysplasia spinulosa-associated human polyomavirus. J Cutan Pathol 2011; 38(5): 420–431.
7. Rouanet J, Aubin F, Gaboriaud P, et al. Trichodysplasia spinulosa: a polyomavirus infection specifically targeting follicular keratinocytes in immunocompromised patients. Br J Dermatol 2016; 174(3): 629–632.
8. Pedergnana V, Martel-Jantin C, Nicol JTJ, et al. Trichodysplasia spinulosa polyomavirus infection occurs during early childhood with intrafamilial transmission, especially from mother to child. J Invest Dermatol 2017; 137(5): 1181–1183.
9. Sheu JC, Tran J, Rady PL, et al. Polyomaviruses of the skin: integrating molecular and clinical advances in an emerging class of viruses. Br J Dermatol 2019; 180(6): 1302–1311.
10. Van der Meijden E, Horváth B, Nijland M, et al. Primary polyomavirus infection, not reactivation, as the cause of trichodysplasia spinulosa in immunocompromised patients. J Infect Dis 2017; 215(7): 1080–1084.
11. Frigerio A, Toptan T, Chang Y, et al. Widespread keratosis pilaris-like eruption in an immunocompromised child. JAD Case Rep 2019; 5(4): 352–354.
12. DeCrescenzo AJ, Philips RC and Wilkerson MG. Trichodysplasia spinulosa: a rare complication of immunosuppression. JAD Case Rep 2016; 2(4): 307–309.
13. Fischer MK, Kao GF, Nguyen HP, et al. Specific detection of trichodysplasia spinulosa-associated polyomavirus DNA in skin and renal allograft tissues in a patient with trichodysplasia spinulosa. Arch Dermatol 2012; 148(6): 726–733.
14. Lichtenberger JJ, Abdelmalek M, Wang RC, et al. Two cases of trichodysplasia spinulosa responsive to compounded topical cidofovir 3% cream. JAD Case Rep 2015; 1(6): S33–S45.
15. Kassar R, Chang J, Chan AW, et al. Lefunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient. Transpl Infect Dis 2017; 19(4): 12702.
16. Barton M, Lockhart S, Sidbury R, et al. Trichodysplasia spinulosa in a 7-year-old boy managed using physical extraction of keratin spicules. Pediatr Dermatol 2017; 34(2): e74–e76.
17. Aleissa M, Konstantinou MP, Samimi M, et al. Trichodysplasia spinulosa associated with HIV infection: clinical response to acitretin and valganciclovir. Clin Exp Dermatol 2018; 43(2): 231–233.